Accepted Manuscript

Title: Randomized Phase II Study of Fulvestrant and Erlotinib Compared With Erlotinib Alone in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer

Authors: Edward B. Garon, Jill M. Siegfried, Laura P. Stabile, Patricia A. Young, Diana C. Marquez-Garban, David J. Park, Ravi Patel, Eddie H. Hu, Saeed Sadeghi, Rupesh J. Parikh, Karen L. Reckamp, Brad Adams, Robert M. Elashoff, David Elashoff, Tristan Grogan, He-Jing Wang, Sanja Dacic, Meghan Brennan, Yacgley Valdes, Simon Davenport, Steven M. Dubinett, Michael F. Press, Dennis J. Slamon, Richard J. Pietras



PII:	S0169-5002(18)30422-7
DOI:	https://doi.org/10.1016/j.lungcan.2018.06.013
Reference:	LUNG 5680
To appear in:	Lung Cancer
Received date:	27-3-2018
Revised date:	6-6-2018
Accepted date:	9-6-2018

Please cite this article as: Garon EB, Siegfried JM, Stabile LP, Young PA, Marquez-Garban DC, Park DJ, Patel R, Hu EH, Sadeghi S, Parikh RJ, Reckamp KL, Adams B, Elashoff RM, Elashoff D, Grogan T, Wang H-Jing, Dacic S, Brennan M, Valdes Y, Davenport S, Dubinett SM, Press MF, Slamon DJ, Pietras RJ, Randomized Phase II Study of Fulvestrant and Erlotinib Compared With Erlotinib Alone in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer, *Lung Cancer* (2018), https://doi.org/10.1016/j.lungcan.2018.06.013

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Title: Randomized Phase II Study of Fulvestrant and Erlotinib Compared With Erlotinib Alone in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer

Authors: Edward B. Garon^a, Jill M. Siegfried^b, Laura P. Stabile^c, Patricia A. Young^a, Diana C. Marquez-Garban^a, David J. Park^d, Ravi Patel^f, Eddie H. Hu^a, Saeed Sadeghi^{a,} Rupesh J. Parikh^e, Karen L. Reckamp^g, Brad Adams^a, Robert M. Elashoff^a, David Elashoff^a, Tristan Grogan^a, He-Jing Wang^a, Sanja Dacic^c, Meghan Brennan^a, Yacgley Valdes^h, Simon Davenportⁱ, Steven M. Dubinett^a, Michael F. Pressⁱ, Dennis J. Slamon^a, and Richard J. Pietras^a

Affiliations:

^a David Geffen School of Medicine at UCLA and Jonsson Comprehensive Cancer Center, 2825 Santa Monica Blvd, Suite 200, Santa Monica, CA, USA

^b University of Minnesota, Masonic Cancer Center, 420 Delaware Street SE, NHH 3-112; CCRB

3-130 Minneapolis, MN 55455, USA;

^c University of Pittsburgh Cancer Institute, Department of Pharmacology & Chemical Biology,

5117 Centre Avenue, Lab 2.7, Pittsburgh, PA 15232, USA;

^d St. Jude Heritage Healthcare, Virginia K. Crosson Cancer Center, 2151 N. Harbor Boulevard, Suite 2200, Fullerton, CA 92835, USA

^e Comprehensive Cancer Care Centers of Nevada, 10001 So. Eastern Ave., Suite 108,

Henderson, NV 89052, USA;

^f Comprehensive Blood and Cancer Center, 6501 Truxtun Avenue, Bakersfield, CA 93309, USA;

^g City of Hope, 1500 E Duarte Rd, Duarte, CA 91010, USA;

^h Translational Research in Oncology, 8-684 Factor Building, Box 951781

Los Angeles, CA 90095-1781 Los Angeles, CA, USA;

ⁱ University of Southern California School of Medicine and Norris Comprehensive Cancer

Center, 1441 Eastlake Ave, Los Angeles, CA 90089, USA;

Download English Version:

https://daneshyari.com/en/article/8453620

Download Persian Version:

https://daneshyari.com/article/8453620

Daneshyari.com